Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 18/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL21111216 | 0.80 | SSTR4 (0.39) | SSTR4 | |
| SCHEMBL19551070 | 0.79 | SSTR4 (0.40) | SSTR4REN | |
| SCHEMBL21191189 | 0.75 | SSTR4 (0.41) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL21111241 | 0.73 | — | — | |
| SCHEMBL3908546 | 0.70 | SSTR4 (0.44) | SSTR4 | |
| SCHEMBL27709202 | 0.69 | SSTR4 (0.40) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL24576137 | 0.68 | — | — | |
| SCHEMBL37447 | 0.68 | — | — | |
| SCHEMBL24690339 | 0.68 | — | — | |
| Phosphine SCHEMBL27533497 | 0.68 | SSTR4 (0.47) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| EP-3508483-B1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2021-10-06 | — | — | EP | disclosed |
| US-20200253971-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-08-13 | — | — | US | disclosed |
| US-10696669-B2 | Dihydropyrimidine compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-06-30 | — | — | US | disclosed |
| US-20190225603-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| EP-3508483-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-07-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166954-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, DHPS, HPRT1 | SSTR4 4659/4885SSTR1 4775/4885SSTR2 4836/4885 |
| US-20190225603-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | DPYD, TYMP, DHPS | SSTR4 4650/4885SSTR1 4810/4885SSTR2 4847/4885 |
| US-20200253971-A1 | DIHYDROPYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | DPYD, DHPS, HPRT1 | SSTR4 4659/4885SSTR1 4775/4885SSTR2 4836/4885 |
| US-10696669-B2 | Dihydropyrimidine compound and preparation method and use thereof | DPYD, TYMP, DHPS | SSTR4 4650/4885SSTR1 4810/4885SSTR2 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.